(Total Views: 1022)
Posted On: 06/11/2020 11:23:17 PM
Post# of 154119
Re: nmbr1stckpckr #37500
At least two doctors of leronlimab covid patients are moving very aggressively towards leronlimab.
On today's call, Pourhassan noted the Dr. Reckner may be personally responsible for filling out the mild/moderate trial.
Montefiore is all in on leronlimab as they have opened up alzheimer's to leronlimab.
UCLA has a large group of patients. The trial manager there, Dr. Otto Yang, seems like a very by-the-book type of guy. This is his first clinical trial that he has ever supervised in his life. He is not likely going off the rails.
Between UCLA and Montefiore, thats about 40 of the 70 EINDs right there.
If the other docs are clinicians who do not usually talk to the FDA, then those other docs may have little leverage to do anything.
On today's call, Pourhassan noted the Dr. Reckner may be personally responsible for filling out the mild/moderate trial.
Montefiore is all in on leronlimab as they have opened up alzheimer's to leronlimab.
UCLA has a large group of patients. The trial manager there, Dr. Otto Yang, seems like a very by-the-book type of guy. This is his first clinical trial that he has ever supervised in his life. He is not likely going off the rails.
Between UCLA and Montefiore, thats about 40 of the 70 EINDs right there.
If the other docs are clinicians who do not usually talk to the FDA, then those other docs may have little leverage to do anything.
(2)
(0)
